Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our Websites |
     
  3. Global Business Websites |
     
  4. Contact |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce font size Increase font size  
 
 
Quality Generics - It matters what's inside - Zentiva A Sanofi Company

Contact

Sanofi

Sanofi House
44 on Grand Central Office Park
2 Bond Street
Grand Central Extension 1
Midrand 16

Tel: +27 (0)11 256 3700
Fax: +27 (0)11 847 5099

If your question is related to an emergency, please consult your doctor or emergency unit.

Medical Information and Pharmacovigilance


Content :

Generics - Zentiva

Zentiva is an international pharmaceutical company that develops, manufactures and markets modern quality generic products. Zentiva’s mission is to increase the availability of modern high quality affordable medicines to patients through primary care providers by developing, manufacturing and marketing pharmaceutical products that improve the quality of human life. Made up of more than 500 products in the form of 800 drug forms, Zentiva product portfolio covers a wide range of therapeutic areas including products for cardiovascular diseases, pain treatment, disorders of central nervous system, digestion system, urinary tract and genital system, and female healthcare. Since 2009, Zentiva is a member of the Sanofi group.

 

Zentiva, the 3rd largest and fastest growing generics company launches in South Africa.

Zentiva launches in South Africa, in 2009, Sanofi acquired Zentiva as part of the company’s strategy to diversify its business. With the inclusion of the Zentiva portfolio, Sanofi is now able to reach more patients and offer them reliable, affordable, quality medications. Zentiva, is a key element of Sanofi’s strategy and plays an increasingly important role within the Group’s diversification strategy focused on patients’ needs.

In 2011, the company expanded use of the Zentiva brand to reach all European Countries, Russia and Turkey. In Western Europe, Zentiva replaced Winthrop as the brand for our Sanofi generic business. Currently, Zentiva is the third largest and one of the fastest growing generics companies in Europe, employing more than 6500 employees.

In 2013, Sanofi is looking to expand the generics business in Africa by incorporating its existing generic portfolio under the Zentiva umbrella, and in the Middle East by launching its generics business through introducing Zentiva. South Africa is the first in Africa to launch Zentiva replacing the Winthrop brand. The generics portfolio expansion is considered as a key growth driver for emerging markets in 2013 and beyond.

pix

“Zentiva, as part of the Sanofi group is committed to excellence in generic medicines. The decision to use the Zentiva brand in South Africa is an important milestone for us as we work towards our goal of providing more modern high quality affordable generic medicines. We are constantly developing our portfolio to extend our therapeutic offer to patients and healthcare providers”, declared John Fagan, General Manager, Sanofi South Africa. “Our ambition is to be one of the Generics top players in all of our markets. Sanofi is always committed to endeavouring to ensure that as wide a section of patients as possible have access to our products“.

Our broad product portfolio includes products in all the main therapeutic areas. Our key product groups include anti-infectives, cardiovascular medicines, pain medicines, central nervous system disorders, Respiratory, female health and gastrointestinal disease.

With the launch of Zentiva in South Africa, Sanofi continues to demonstrate its commitment towards meeting the needs of the 7 billion people around the world.

Updated May 13, 2013

Module :